RxDoctor Payments Data

Alexander Feldman, MD

Neurology · Denver, CONPI 1134179914

Payments from drug & device makers

$61,076in general payments, 2019–2025

Across 1,308 payments — averaging $46.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$28K
  • H. Lundbeck A S$6K
  • AbbVie$4K
  • UCB, Inc.$2K
  • Pfizer$2K
  • Novartis$1K
  • plus $17K from 54 others

What the payments were for

  • Food & beverage$27,465100%
  • Education$1160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.41$28,214
H. Lundbeck A S2$6,000
AbbVie(2 entities)218$4,423
UCB, Inc.78$2,029
Pfizer90$1,647
Novartis81$1,331
AstraZeneca(2 entities)45$1,132
Abbott17$953
EMD Serono, Inc.39$900
Mallinckrodt Hospital Products Inc.51$900
Lilly USA, LLC45$844
SK Life Science, Inc.33$810
Merz Pharmaceuticals, LLC46$744
Eisai Inc.35$710
Amneal Pharmaceuticals LLC31$632
Biogen29$628
MDD US Operations, LLC32$598
Amgen19$502
Acadia Pharmaceuticals Inc25$499
Neurelis, Inc.15$424
Sanofi16$402
Harmony Biosciences LLC13$398
Argenx US, Inc.16$386
Biohaven Pharmaceuticals, Inc.14$370
TG Therapeutics, Inc.12$367
Lundbeck LLC20$365
Jazz Pharmaceuticals Inc.15$362
Genentech USA, Inc.11$320
Supernus Pharmaceuticals, Inc.27$311
Mallinckrodt Enterprises LLC27$295
Alnylam Pharmaceuticals Inc.11$260
Neurocrine Biosciences, Inc.12$251
Vanda Pharmaceuticals Inc.7$224
Axsome Therapeutics, Inc.8$218
Biohaven Pharmaceutical Holding Company Ltd.10$212
Catalyst Pharmaceuticals, Inc.7$210
Bristol Myers Squibb8$197
Merz North America, Inc.8$170
Otsuka America Pharmaceutical, Inc.7$132
Kyowa Kirin, Inc.5$121
Grifols USA, LLC6$120
Boston Scientific5$115
Tanabe Pharma America, Inc.6$109
Octapharma USA, Inc.5$103
ANI Pharmaceuticals, Inc.4$85
Medtronic(2 entities)5$84
Johnson & Johnson(2 entities)4$81
Bausch Health US, LLC4$81
Avanir Pharmaceuticals, Inc.4$80
Banner Life Sciences, LLC4$70
Insightec,inc3$65
Takeda Pharmaceuticals U.S.A., Inc.2$62
Springworks Therapeutics, Inc.2$57
Amylyx Pharmaceuticals, Inc.2$45
E.r. Squibb & Sons, L.L.C.3$43
Collegium Pharmaceutical, Inc.2$33
Almatica Pharma LLC1$31
Nevro Corp.1$27
Nobelpharma America, LLC2$27
NS Pharma, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,076 in reported general payments places this provider in the 80th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$324,986
Medicare patients
329
Services billed
28,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin16$196,309
AustedoDeutetrabenazine23$164,221
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$108,425
BotoxOnabotulinumtoxina62$87,102
CopaxoneGlatiramer Acetate11$63,122
NeuproRotigotine22$20,810
RytaryCarbidopa/Levodopa13$19,192
Aimovig AutoinjectorErenumab-Aooe26$19,118
Nurtec OdtRimegepant Sulfate18$18,278
Emgality PenGalcanezumab-Gnlm13$16,526
UbrelvyUbrogepant12$11,811
Memantine Hcl113$5,367
Propranolol Hcl ErPropranolol Hcl54$2,029
Carbidopa-LevodopaCarbidopa/Levodopa82$1,565
Gabapentin145$1,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$28,214$227,34334 claims
EMD Serono, Inc.Rebif$900$196,30916 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$62$108,42513 claims
AbbVieBotox, Ubrelvy$4,423$98,91374 claims
UCB, Inc.Neupro$2,029$20,81022 claims
Amneal Pharmaceuticals LLCRytary$632$19,19213 claims
PfizerNurtec Odt$1,647$18,27818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 334 neurology providers in Colorado.

Other neurology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →